Evotec (NASDAQ:EVO) Sets New 52-Week Low – What’s Next?

Evotec AG (NASDAQ:EVO) shares reached a new 52-week low during trading on Monday . The stock traded as low as $1.56 and last traded at $1.5550, with a volume of 99869 shares changing hands. The stock had previously closed at $1.60.

Key Stories Impacting Evotec

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: Evotec’s pipeline continues to advance, and potential momentum from partnerships and drug-development programs could provide future commercial upside if milestones translate into revenue. The company may also benefit from growing interest in converting injectable medicines into oral treatments. Evotec’s Pipeline Advances as Shareholders Confront a 48% Slide Novo Nordisk, BioNxt Solutions, Evotec: When injections become pills, the cash starts rolling in
• Neutral Sentiment: Evotec’s scientific operations remain active, while management and its CFO are attempting to reassure investors about the turnaround. However, the market appears to be waiting for measurable improvement in earnings and cash generation before assigning value to those initiatives. Evotec’s Science Engine Keeps Running as Investors Stay on the Sidelines Evotec’s CFO Offers a Lifeline, but the Numbers Still Have to Catch Up
• Negative Sentiment: The main bearish concern is deteriorating fundamentals. First-half 2026 revenue reportedly fell nearly 20%, adjusted EBITDA turned sharply negative, and turnaround targets have been pushed out. Investors are demanding proof that cost controls will work, with one analysis assigning little value to future guidance. Evotec: The Market Seems Split On The Company’s Prospects, Buy Evotec Bets on Pipeline Momentum While the Market Demands Proof on Costs Shares also reached or closed near a new 52-week low, reinforcing the weak technical sentiment. Evotec stock falls as shares reach a new 52-week low Evotec stock ends the day near 52-week low at the close on Nasdaq

Analyst Ratings Changes

A number of research analysts have commented on the company. Berenberg Bank lowered Evotec from a “buy” rating to a “hold” rating in a research report on Thursday, July 16th. HC Wainwright lowered their price objective on Evotec from $7.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, July 15th. Weiss Ratings downgraded shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 25th. Finally, TD Cowen cut shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target for the company. in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $3.00.

Evotec Price Performance

The company has a current ratio of 2.33, a quick ratio of 2.21 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average price of $1.89 and a 200-day moving average price of $2.48.

Institutional Investors Weigh In On Evotec

Several large investors have recently bought and sold shares of EVO. Apollon Wealth Management LLC bought a new position in Evotec during the first quarter worth about $28,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Evotec during the first quarter worth about $44,000. Fore Capital LLC bought a new position in shares of Evotec during the 4th quarter valued at about $97,000. WCM Investment Management LLC lifted its holdings in shares of Evotec by 12.1% during the 1st quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock valued at $1,480,000 after purchasing an additional 67,917 shares in the last quarter. Finally, Optiver Holding B.V. grew its position in shares of Evotec by 598.4% in the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock valued at $709,000 after purchasing an additional 242,973 shares during the period. Institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic organizations. The company works across the research process, from early-stage target identification and assay development through hit identification, lead optimization, preclinical research and translational development.

Evotec uses technology platforms and scientific expertise in areas including small-molecule drug discovery, biologics, protein degradation, cell and gene therapy, and precision medicine.